Ján Kliment, Monika Kuzma
Until the year 2015, androgene deprivation therapy (ADT) was the standard treatment of metastatic hormone sensitive
prostate cancer (mHSPC). In the year 2015 the results from clinical studies CHAARTED and STAMPEDE-docetaxel
were published and proved significant prolongation of survival if ADT was supplemented with docetaxel in
patients with mHSPC. The results of the studies led to a change in standard mHSPC treatment. In the year 2017,
clinical trials LATITUDE and STAMPEDE-abiraterone presented similar improvement in survival when abiraterone
and prednisone were added to ADT in patients with mHSPC.
In the work the results of randomized phase III clinical trials were published, which investigated docetaxel or abiraterone
together with prednisone added to ADT in patients with mHSPC.